Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30785121 | 1.00 | KDM4E (0.53) | KDM4EALDH1A1KMT2AMEN1POLB | |
| SCHEMBL7661925 | 0.85 | ALDH1A1 (0.49) | KDM4EALDH1A1KMT2AMEN1POLB | |
| SCHEMBL8342657 | 0.85 | KDM4E (0.47) | KDM4EALDH1A1KMT2AMEN1POLB | |
| SCHEMBL4625651 | 0.84 | SLC6A4 (0.49) | KDM4EALDH1A1KMT2AMEN1POLB | |
| SCHEMBL12844526 | 0.83 | HMGCR (0.53) | KDM4ESLC6A4SLC6A2SLC6A3TAAR1 | |
| SCHEMBL15417752 | 0.83 | L3MBTL1 (0.52) | KDM4EALDH1A1KMT2AMEN1POLB | |
| SCHEMBL18977773 | 0.81 | L3MBTL1 (0.51) | KDM4EALDH1A1KMT2AMEN1POLB | |
| SCHEMBL1714408 | 0.81 | SLC6A2 (0.46) | KDM4EALDH1A1KMT2AMEN1POLB | |
| SCHEMBL1663130 | 0.81 | SLC6A2 (0.46) | KDM4EALDH1A1KMT2AMEN1POLB | |
| SCHEMBL16892264 | 0.81 | ALDH1A1 (0.53) | KDM4EALDH1A1KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577644-A1 | BIOCATALYSTS AND METHODS THEREOF | Tesaro, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024044657-A1 | BIOCATALYSTS AND METHODS THEREOF | TESARO, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230145305-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230137110-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE THEREOF | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-3967696-A1 | COMPOUND USED AS KINASE INHIBITOR AND APPLICATION THEREOF | TYK Medicines Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-10980816-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2021-04-20 | — | — | US | disclosed |
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | US | disclosed |
| WO-2020224626-A1 | COMPOUND USED AS KINASE INHIBITOR AND APPLICATION THEREOF | 浙江同源康医药股份有限公司 | 2020-11-12 | — | — | WO | disclosed |
| US-20200323874-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2020-10-15 | — | — | US | disclosed |
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1829877-A1 | BICYCLIC PYRROLE DERIVATIVES | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
| US-20040152736-A1 | Thrombin receptor antagonists | TOPROL ACQUISITION LLC | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885ALDH1A1 4827/4885KMT2A 206/4885 |
| US-20230145305-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | KDM4E 1278/4885ALDH1A1 4774/4885KMT2A 1204/4885 |
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | KDM4E 2716/4885ALDH1A1 2315/4885KMT2A 2229/4885 |
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | KDM4E 3005/4885ALDH1A1 1326/4885KMT2A 4310/4885 |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | CRHR1, CRHR2, CRH | KDM4E 4180/4885ALDH1A1 1525/4885KMT2A 3165/4885 |
| US-20230137110-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE THEREOF | SLCO2B1, SLCO2A1, SLCO1B3 | KDM4E 878/4885ALDH1A1 1189/4885KMT2A 2938/4885 |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | KDM4E 1817/4885ALDH1A1 3710/4885KMT2A 3156/4885 |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | KDM4E 2229/4885ALDH1A1 814/4885KMT2A 2415/4885 |
| US-20040152736-A1 | Thrombin receptor antagonists | CNR1, TBXA2R, CNR2 | KDM4E 4442/4885ALDH1A1 3033/4885KMT2A 4099/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | KDM4E 1442/4885ALDH1A1 823/4885KMT2A 4050/4885 |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRM1 | KDM4E 327/4885ALDH1A1 2178/4885KMT2A 721/4885 |
| US-20200323874-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | KDM4E 3388/4885ALDH1A1 100/4885KMT2A 3216/4885 |
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | TBXA2R, HTR2C, NPY1R | KDM4E 2362/4885ALDH1A1 809/4885KMT2A 2425/4885 |
| US-10980816-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | DPYD, TYMP, DHFR | KDM4E 2998/4885ALDH1A1 69/4885KMT2A 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.